These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results
These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results
Silence Therapeutics Plc (NASDAQ:SLN) reported a loss for 2023 on Wednesday.
Silence Therapeutics Plc（納斯達克股票代碼：SLN）週三公佈了2023年的虧損。
The company reported a loss per share of (38.9) pence for 2023, narrower than the (41.9) pence loss per share a year ago, according to data from Benzinga Pro. Collaboration revenues were £25.4 million versus £17.501 million a year ago. Net loss was £(43.3) million for 2023, compared to a net loss of £(40.5) million in 2022.
根據Benzinga Pro的數據，該公司報告2023年每股虧損爲（38.9）便士，低於去年同期的每股虧損（41.9）便士。合作收入爲2540萬英鎊，去年同期爲17501萬英鎊。2023年的淨虧損爲4,330萬英鎊，而2022年的淨虧損爲4,050萬英鎊。
"We ended December 2023 with approximately $68.8 million and significantly increased our cash position in early 2024 to over $200 million," said Rhonda Hellums, Chief Financial Officer of Silence.
Silence首席財務官朗達·海勒姆斯表示：“截至2023年12月，我們的現金狀況約爲6,880萬美元，並在2024年初大幅增加到2億美元以上。”
Silence also announced topline 36-week data from the ongoing ALPACAR-360 phase 2 study of zerlasiran in patients with a median baseline Lp(a) of approximately 215 nmol/L.
Silence還公佈了正在進行的針對zerlasiran的 ALPACAR-360 2期研究的36周主要數據，該研究針對中位基線Lp（a）約爲215 nmol/L的患者。
"We are excited to have multiple programs advancing in the clinic, supported by a substantial cash position that extends our estimated runway into 2026," Hellums added.
Hellums補充說：“我們很高興在大量現金狀況的支持下，臨床上有多個項目正在取得進展，這使我們的預計投資期延長至2026年。”
Silence Therapeutics shares fell 3.9% to close at $24.62 on Wednesday.
週三，Silence Therapeutics股價下跌3.9％，收於24.62美元。
These analysts made changes to their price targets on Silence Therapeutics after announcing quarterly results.
這些分析師在公佈季度業績後更改了Silence Therapeutics的目標股價。
- Chardan Capital raised the price target on Silence Therapeutics from $26 to $42. Chardan Capital analyst Keay Nakae maintained a Buy rating.
- Morgan Stanley boosted the price target on Silence Therapeutics from $29 to $45. Morgan Stanley analyst Michael Ulz maintained an overweight rating.
- Chardan Capital將Silence Therapeutics的目標股價從26美元上調至42美元。查丹資本分析師凱伊·納卡埃維持買入評級。
- 摩根士丹利將Silence Therapeutics的目標股價從29美元上調至45美元。摩根士丹利分析師邁克爾·烏爾茲維持增持評級。
譯文內容由第三人軟體翻譯。